Eli Lilly And (LLY) Rising Before The Market Opens

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Eli Lilly and ( LLY) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Eli Lilly and as such a stock due to the following factors:

  • LLY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $606.9 million.
  • LLY traded 21,561 shares today in the pre-market hours as of 9:27 AM.
  • LLY is up 2.4% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in LLY with the Ticky from Trade-Ideas. See the FREE profile for LLY NOW at Trade-Ideas

More details on LLY:

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The stock currently has a dividend yield of 2.4%. LLY has a PE ratio of 4. Currently there are 7 analysts that rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for Eli Lilly and has been 4.9 million shares per day over the past 30 days. Eli Lilly and has a market cap of $92.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.43 and a short float of 2.4% with 3.51 days to cover. Shares are up 19.8% year-to-date as of the close of trading on Tuesday.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief